Nicotine metabolism mostly usually takes position inside the liver. Consequently, when nicotine is administered with the GI method, it undergoes initially-go metabolism by the liver, resulting in a bioavailability of only about 20%. This method inherently decreases the bioavailability of nicotine inside the system and should lead to adverse GI outc